These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

329 related articles for article (PubMed ID: 12472376)

  • 1. The Ca2+-activated K+ channel of intermediate conductance:a possible target for immune suppression.
    Jensen BS; Hertz M; Christophersen P; Madsen LS
    Expert Opin Ther Targets; 2002 Dec; 6(6):623-36. PubMed ID: 12472376
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Ca2+-activated K+ channel of intermediate conductance: a molecular target for novel treatments?
    Jensen BS; Strøbaek D; Olesen SP; Christophersen P
    Curr Drug Targets; 2001 Dec; 2(4):401-22. PubMed ID: 11732639
    [TBL] [Abstract][Full Text] [Related]  

  • 3. K+ channel blockers: novel tools to inhibit T cell activation leading to specific immunosuppression.
    Panyi G; Possani LD; Rodríguez de la Vega RC; Gáspár R; Varga Z
    Curr Pharm Des; 2006; 12(18):2199-220. PubMed ID: 16787250
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anuroctoxin, a new scorpion toxin of the alpha-KTx 6 subfamily, is highly selective for Kv1.3 over IKCa1 ion channels of human T lymphocytes.
    Bagdány M; Batista CV; Valdez-Cruz NA; Somodi S; Rodriguez de la Vega RC; Licea AF; Varga Z; Gáspár R; Possani LD; Panyi G
    Mol Pharmacol; 2005 Apr; 67(4):1034-44. PubMed ID: 15615696
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of T cell proliferation by selective block of Ca(2+)-activated K(+) channels.
    Jensen BS; Odum N; Jorgensen NK; Christophersen P; Olesen SP
    Proc Natl Acad Sci U S A; 1999 Sep; 96(19):10917-21. PubMed ID: 10485926
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potassium channels as therapeutic targets for autoimmune disorders.
    Wulff H; Beeton C; Chandy KG
    Curr Opin Drug Discov Devel; 2003 Sep; 6(5):640-7. PubMed ID: 14579513
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ca2+-activated K+ channels in murine endothelial cells: block by intracellular calcium and magnesium.
    Ledoux J; Bonev AD; Nelson MT
    J Gen Physiol; 2008 Feb; 131(2):125-35. PubMed ID: 18195387
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Maurotoxin: a potent inhibitor of intermediate conductance Ca2+-activated potassium channels.
    Castle NA; London DO; Creech C; Fajloun Z; Stocker JW; Sabatier JM
    Mol Pharmacol; 2003 Feb; 63(2):409-18. PubMed ID: 12527813
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Ion channels and demyelination: basis of a treatment of experimental autoimmune encephalomyelitis (EAE) by potassium channel blockers].
    Devaux J; Beeton C; Béraud E; Crest M
    Rev Neurol (Paris); 2004 May; 160(5 Pt 2):S16-27. PubMed ID: 15269656
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Selective blockade of T lymphocyte K(+) channels ameliorates experimental autoimmune encephalomyelitis, a model for multiple sclerosis.
    Beeton C; Wulff H; Barbaria J; Clot-Faybesse O; Pennington M; Bernard D; Cahalan MD; Chandy KG; Béraud E
    Proc Natl Acad Sci U S A; 2001 Nov; 98(24):13942-7. PubMed ID: 11717451
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design of a potent and selective inhibitor of the intermediate-conductance Ca2+-activated K+ channel, IKCa1: a potential immunosuppressant.
    Wulff H; Miller MJ; Hansel W; Grissmer S; Cahalan MD; Chandy KG
    Proc Natl Acad Sci U S A; 2000 Jul; 97(14):8151-6. PubMed ID: 10884437
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selective blocking of voltage-gated K+ channels improves experimental autoimmune encephalomyelitis and inhibits T cell activation.
    Beeton C; Barbaria J; Giraud P; Devaux J; Benoliel AM; Gola M; Sabatier JM; Bernard D; Crest M; Béraud E
    J Immunol; 2001 Jan; 166(2):936-44. PubMed ID: 11145670
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of the outer pore region of the apamin-sensitive Ca2+-activated K+ channel rSK2.
    Jäger H; Grissmer S
    Toxicon; 2004 Jun; 43(8):951-60. PubMed ID: 15208028
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Blockage of intermediate-conductance Ca2+-activated K+ channels inhibit human pancreatic cancer cell growth in vitro.
    Jäger H; Dreker T; Buck A; Giehl K; Gress T; Grissmer S
    Mol Pharmacol; 2004 Mar; 65(3):630-8. PubMed ID: 14978241
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interaction of agitoxin2, charybdotoxin, and iberiotoxin with potassium channels: selectivity between voltage-gated and Maxi-K channels.
    Gao YD; Garcia ML
    Proteins; 2003 Aug; 52(2):146-54. PubMed ID: 12833539
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Histamine hyperpolarizes human glioblastoma cells by activating the intermediate-conductance Ca2+-activated K+ channel.
    Fioretti B; Catacuzzeno L; Sforna L; Aiello F; Pagani F; Ragozzino D; Castigli E; Franciolini F
    Am J Physiol Cell Physiol; 2009 Jul; 297(1):C102-10. PubMed ID: 19420000
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Halothane inhibits an intermediate conductance Ca2+-activated K+ channel by acting at the extracellular side of the ionic pore.
    Hashiguchi-Ikeda M; Namba T; Ishii TM; Hisano T; Fukuda K
    Anesthesiology; 2003 Dec; 99(6):1340-5. PubMed ID: 14639146
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Functional dependence of Ca(2+)-activated K+ current on L- and N-type Ca2+ channels: differences between chicken sympathetic and parasympathetic neurons suggest different regulatory mechanisms.
    Wisgirda ME; Dryer SE
    Proc Natl Acad Sci U S A; 1994 Mar; 91(7):2858-62. PubMed ID: 8146200
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibitors of potassium channels KV1.3 and IK-1 as immunosuppressants.
    Pegoraro S; Lang M; Dreker T; Kraus J; Hamm S; Meere C; Feurle J; Tasler S; Prütting S; Kuras Z; Visan V; Grissmer S
    Bioorg Med Chem Lett; 2009 Apr; 19(8):2299-304. PubMed ID: 19282171
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting effector memory T cells with a selective peptide inhibitor of Kv1.3 channels for therapy of autoimmune diseases.
    Beeton C; Pennington MW; Wulff H; Singh S; Nugent D; Crossley G; Khaytin I; Calabresi PA; Chen CY; Gutman GA; Chandy KG
    Mol Pharmacol; 2005 Apr; 67(4):1369-81. PubMed ID: 15665253
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.